Heart failure & cardiomyopathies
Lifetime Clinical Course of Hypertrophic Cardiomyopathy: Outcome of the Historical Florence Cohort Over 5 Decades
Authors' conclusion
In this unique HCM cohort followed for up to 50 years, often before contemporary therapies became widely implemented for HCM, HF frequently progressed over time, while arrhythmic SCD events were less common and remained constant over time. Despite spanning different management eras over 5 decades, HCM-related mortality remained relatively low (1.3%/y).
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) diagnosed at one centre 1970–1992, followed annuallyfollow-up 27 ± 6 years
- Participants
- 202 patients
- Outcome
- HCM-related mortality (HF/stroke-related, SCD) and non-HCM-related mortality
Methodological detailssingle-centre, long-term follow-up
- Single-centre
- Long-term follow-up
Main finding
As reported in the abstract
HCM-related mortality · follow-up 27 ± 6 [range: 3-50] years
- Survived
- 97 (48%)
- Died
- 105 (52%)
- HCM-related deaths
- 69
- HF-related deaths
- 53
- Fatal embolic strokes
- 11
- SCDs
- 16
- Annual overall HCM-related mortality
- 1.3%/y
- Annual HCM-related mortality, first decade vs second/third decade
- 0.7% vs 1.8% (P < 0.01)
- HF-/stroke-related events, first vs second/third decade
- 0.6% vs 1.3%
- SCD mortality rate, similar in the 2 periods
- 0.1% vs 0.44%, P = 0.10
- HCM deaths before widespread effective contemporary treatment, considered potentially preventable
- 29 (42%)
Observational data: associations, not effects.
Original publication
Lifetime Clinical Course of Hypertrophic Cardiomyopathy: Outcome of the Historical Florence Cohort Over 5 Decades. JACC Adv. Published 24 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →